PHARMACOKINETICS OF UNDERSTUDIED DRUGS USED DURING PREGNANCY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 主要目标： 为了估计孕妇在服药期间已经接受的药物PK参数(大多数情况下，计划在整个怀孕期间继续接受)，并将它们与哺乳期间和未怀孕时的PK数据进行比较(在相同的受试者中)。 其基本假设是： 孕妇的药物清除量在怀孕期间(中期/晚期)发生显著变化，并在产后恢复到基线水平。 次要目标： 评估孕妇与(产后)非孕妇的药物PK参数的个体间变异性。评估跨孕期药物与蛋白质的结合，并将PK与相关药物代谢酶的基因和表达相关联。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objective: To estimate drug PK parameters in pregnant women for medication stay are already receiving (and in most cases, plan to continue receiving throughout pregnancy) and to compare them (in the same subjects) with PK data during nursing and in the absence of pregnancy. The underlying hypothesis is that: Drug clearance in pregnant women changes significantly during (the second/third trimesters of) pregnancy and returns to baseline values postpartum. Secondary Objectives: To estimate inter-individual variability of drug PK parameters in pregnant women compared with PK variability in (postpartum) non-pregnant women. To estimate drug-protein binding across pregnancy and to correlate PK with genotype and expression of relevant drug metabolizing enzymes.